Oncological outcomes of patients with oligometastatic oesophagogastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Oligometastatic oesophagogastric cancer, defined by limited metastases and stable disease, shows improved survival compared to multi-metastatic cancer. Surgical management of oligometastases further enhances outcomes.
Area Of Science
- Oncology
- Gastroenterology
Background
- Oligometastatic oesophagogastric cancer (OMC) is defined by limited metastases and oncological stability.
- The prevalence and prognostic impact of OMC remain unclear.
Purpose Of The Study
- To determine the incidence of OMC in a real-world cohort.
- To compare oncological outcomes between OMC and multi-metastatic oesophagogastric cancer (MOC).
Main Methods
- Retrospective analysis of 497 patients with metastatic oesophageal cancer (2017-2021).
- Identification and classification of oligometastatic disease (OMD) based on consensus criteria.
- Comparison of median overall survival (mOS) between OMD and MOC groups.
Main Results
- 36 patients (7.2%) were diagnosed with OMD.
- OMD demonstrated significantly improved mOS compared to MOC (synchronous: 26.8 vs 7.3 months; metachronous: 38.6 vs 6.1 months).
- Surgical management of oligometastases in a subset of OMD patients resulted in superior mOS (60 vs 24.4 months).
Conclusions
- OMC is associated with a significantly better oncological outcome than MOC.
- Aggressive treatment strategies, including surgery, may benefit select OMC patients.
- Further research is warranted to identify OMC patients who will benefit most from intensified treatment approaches.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...